Taken together, our findings show that P61-E7 provides a novel addition to the range of GGTI compounds that are in development as anticancer drugs and that RhoA is an important target of the GGTI compound in Panc-1 pancreatic cancer cells. This evidence concerns the gene RHOA and pancreatic neoplasm.